CAPECITABINE

作品数：111被引量：296H指数：10
导出分析报告
相关领域：医药卫生更多>>
相关作者：刘晓晴宋三泰朱珠付强李文瑜更多>>
相关机构：上海健康医学院成都医学院中国科学技术大学山西白求恩医院(山西医学科学院)更多>>
相关期刊：更多>>
相关基金：国家自然科学基金国家重点基础研究发展计划广东省自然科学基金中国博士后科学基金更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Nab-paclitaxel plus capecitabine as a first-line regimen for advanced biliary tract cancers:Feasible or not feasible?
《World Journal of Gastroenterology》2025年第10期134-138,共5页Jian-Qiang Chen Xiang Lan 
A clinical trial of nab-paclitaxel plus capecitabine as a first-line treatment for advanced biliary tract cancers was conducted.We analyzed the development of systemic therapy recommended by the National Comprehensive...
关键词：NAB-PACLITAXEL CAPECITABINE Biliary tract cancers Systemic therapy Firstline regimen 
Addition of SHR-1701 to first-line capecitabine and oxaliplatin(XELOX) plus bevacizumab for unresectable metastaticcolorectal cancer
《Signal Transduction and Targeted Therapy》2025年第1期340-349,共10页Miao-Zhen Qiu Yuxian Bai Jufeng Wang Kangsheng Gu Mudan Yang Yifu He Cheng Yi Yongdong Jin Bo Liu Feng Wang Yu-kun Chen Wei Dai Yingyi Jiang Chuanpei Huang Rui-Hua Xu Hui-Yan Luo 
supported by Jiangsu Hengrui Pharmaceuticals and the following grants:the National Natural Science Foundation of China(NSFC:82321003,82173128,82073377,81930065);the Natural Science Foundation of Guangdong(2021A1515012439);Guangdong Basic and Applied Basic Research Foundation(2024B1515020120);the CAMS Innovation Fund for Medical Sciences(CIFMS:2019-I2M-5-036);Additional funding was provided by the Cancer Innovative Research Program of Sun Yat-sen University Cancer Center(CIRP-SYSUCC-0004).
This phase 2/3 trial (NCT04856787) assessed the efficacy and safety of SHR-1701, a bifunctional protein targeting PD-L1 and TGF-β,in combination with BP102 (a bevacizumab biosimilar) and XELOX (capecitabine plus oxal...
关键词：BEVACIZUMAB colorectal SHR 
Temozolomide and capecitabine regimen as first-line treatment in advanced gastroenteropancreatic neuroendocrine tumors at a Latin American reference center
《World Journal of Gastrointestinal Oncology》2024年第12期4675-4684,共10页Wagner Eduardo Cruz-Diaz Victor Paitan Jersinho Medina Raymundo Flores Juan Haro-Varas Raul Mantilla Victor Castro-Oliden 
BACKGROUND Numerous studies have indicated that the temozolomide and capecitabine regimen(TEMCAP)exhibits a certain level of efficacy in treating advanced,welldifferentiated gastroenteropancreatic neuroendocrine tumor...
关键词：WELL-DIFFERENTIATED Gastroenteropancreatic neuroendocrine tumors CAPECITABINE TEMOZOLOMIDE Retrospective study Treatment CHEMOTHERAPY 
Postoperative chemoradiotherapy with capecitabine and oxaliplatin vs.capecitabine for pathological stage N2 rectal cancer
《Chinese Journal of Cancer Research》2024年第5期577-586,共10页Ning Li Yuan Zhu Luying Liu Yanru Feng Wenling Wang Jun Wang Hao Wang Gaofeng Li Yuan Tang Chen Hu Wenyang Liu Hua Ren Shulian Wang Weihu Wang Yongwen Song Yueping Liu Hui Fang Yu Tang Ningning Lu Bo Chen Shunan Qi Yexiong Li Jing Jin 
supported by grants from Sanming Project of Medicine in Shenzhen(No.SZSM202211030);the Science and Technology Department Basic Research Project of Shanxi(No.202203021221284)。
Objective:Several studies have been conducted on the effects and toxicity of adding oxaliplatin to fluorouracilbased or capecitabine-based chemoradiotherapy(CRT)regimens as significantly increasing the toxic response ...
关键词：CHEMORADIOTHERAPY OXALIPLATIN CAPECITABINE rectal neoplasms drug therapy RADIOTHERAPY treatment outcome 
Neoadjuvant chemotherapy with capecitabine combined with oxaliplatin for mid-low locally advanced rectal cancer with negative mesorectal fascia:Long-term outcomes of a prospective trial(PKUCH-R03 trial)
《Chinese Journal of Cancer Research》2024年第4期410-420,共11页Nan Chen Minghe Zhao Yunfeng Yao Lin Wang Yifan Peng Tingting Sun Tiancheng Zhan Jun Zhao Aiwen Wu 
supported by Beijing Municipal Administration of Hospitals Incubating Program (No.PZ2020027);Beijing Talent Incubating Funding (No.2019-4);National Natural Science Foundation of China (No.81773214);Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support (No.ZYLX202116);2019 Major and Difficult Diseases Chinese and Western Medicine Coordination Capacity Colorectal Cancer Project [No.(2018)275];Science Foundation of Peking University Cancer Hospital-2023 (No.JC202310)
Objective:To evaluate the safety and efficacy of neoadjuvant chemotherapy(NCT)in mid-low locally advanced rectal cancer with negative mesorectal fascia(MRF).Methods:This prospective,single-arm phaseⅡtrial was designe...
关键词：Neoadjuvant chemotherapy rectal cancer mesorectal fascia disease-free survival anal function 
Nab-paclitaxel plus capecitabine as first-line treatment for advanced biliary tract cancers:An open-label,non-randomized,phase II clinical trial被引量：1
《World Journal of Gastroenterology》2024年第30期3564-3573,共10页Ling-Xiao Xu Jia-Jia Yuan Ran Xue Jun Zhou 
BACKGROUND Biliary tract cancers(BTCs)are a heterogeneous group of tumors with high malignancy,poor prognosis,and limited treatment options.AIM To explore the efficacy and safety of nab-paclitaxel plus capecitabine as...
关键词：NAB-PACLITAXEL CAPECITABINE Biliary tract cancer Objective response rate Phase II clinical trial 
XELOX(capecitabine plus oxaliplatin)plus bevacizumab(anti-VEGF-A antibody)with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer:a multicenter,open-label,randomized,controlled,phase 3 trial被引量：1
《Signal Transduction and Targeted Therapy》2024年第5期2104-2113,共10页Qiu-Zhong Pan Jing-Jing Zhao Liang Liu Dong-Sheng Zhang Li-Ping Wang Wen-Wei Hu De-Sheng Weng Xiang Xu Yi-Zhuo Li Yan Tang Wei-Hong Zhang Jie-Yao Li Xiao Zheng Qi-Jing Wang Yong-Qiang Li Tong Xiang Li Zhou Shuang-Ning Yang Chen Wu Rong-Xing Huang Jia He Wei-Jiao Du Lu-Jun Chen Yue-Na Wu Bin Xu Qiong Shen Yi Zhang Jing-Ting Jiang Xiu-Bao Ren Jian-Chuan Xia 
This study was funded by the National Key R&D Program of China for J‐CX(grant number 2018YFC1313400);the National Natural Science Foundation of China for J.‐C.X.(grant number 81773110).We express our gratitude to all participating patients and their families,as well as to the study groups and investigators from the participating centers.
Fluoropyrimidine-based combination chemotherapy plus targeted therapy is the standard initial treatment for unresectable metastatic colorectal cancer(mCRC),but the prognosis remains poor.This phase 3 trial(ClinicalTri...
关键词：PD1 immunotherapy BEVACIZUMAB 
Evaluating combined bevacizumab and XELOX in advanced colorectal cancer: Serum markers carcinoembryonic antigen, carbohydrate antigen 125, carbohydrate antigen 199 analysis
《World Journal of Clinical Cases》2024年第1期15-23,共9页Dong-Bing Zhou Jun Cheng Xiong-Hui Zhang 
BACKGROUND Colorectal cancer ranks third and second among common and fatal cancers.The treatment of metastatic colorectal cancer(mCRC)is generally based on XELOX in clinical practice,which includes capecitabine(CAP)an...
关键词：Metastatic colorectal cancer BEVACIZUMAB CAPECITABINE XELOX Tumor markers 
Correction to“Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first-line options for HER2-positive relapsed or metastatic breast cancer”
《Cancer Innovation》2023年第4期318-318,共1页
Guan X,Ma F,Xu B.Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first-line options for HER2-positive relapsed or metastatic breast cancer.Cancer Innovation.2022;1-5...
关键词：BREAST RANDOMIZED METASTATIC 
Mitomycin C and capecitabine: An additional option as an advanced line therapy in patients with metastatic colorectal cancer
《World Journal of Gastrointestinal Oncology》2023年第11期1913-1924,共12页Gil Mullin Michal Sternschuss Yosef Landman Aaron Sulkes Baruch Brenner 
The study was reviewed and approved by the Rabin Medical Center Institutional Review Board(Approval No.0639-19-RMC).
BACKGROUND In recent years survival of patients with metastatic colorectal cancer(mCRC),though still limited,has improved significantly;clearly,when the disease becomes refractory to standard regimens,additional treat...
关键词：Colorectal cancer Metastatic cancer Chemotherapy Mitomycin C/Capecitabine Advanced line treatment 
全选清除导出
共12页<12345678910>
检索报告 对象比较 聚类工具 使用帮助 返回顶部